HVTN 135, NCT04607408: Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants |
|
|
| Completed | 1 | 38 | RoW | CH505TF gp120, GLA-SE adjuvant, Placebo | HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 07/24 | 07/24 | | |
NCT04860323: Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 703/HPTN 081 AMP Study |
|
|
| Active, not recruiting | N/A | 13 | RoW | Analytical Treatment Interruption | HIV Vaccine Trials Network, National Institute of Allergy and Infectious Diseases (NIAID), HIV Prevention Trials Network, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | HIV Infection | 02/25 | 02/25 | | |
